The trans-differentiation of ECs from other tumor types, such as gliomas and melanomas, is well-established and may explain their resistance to anti-angiogenic agents that target proteins such as vascular endothelial growth factor, which recruit pre-existing exogenous ECs residing in proximity to tumors [34,39,41,42,77,90,91]. The gene discussed is VEGFA; the disease is melanoma.